• Skip to main content
  • Skip to footer

Delphi Diagnostics

Delphi Diagnostics guides personalized breast cancer therapy decisions with SET.

  • Our Technology
    • Lead Inventor
    • Breast Cancer Diagnostic Tests
    • Intellectual Property
  • Our Mission
  • Our Company
    • Board of Directors
    • Executive Team
    • Advisory Board
    • Trusted Collaborators
  • News
  • Contact Us

Uncategorized

Delphi Diagnostics™ Inc and Quantum Leap Healthcare Collaborative™ Announce the Inclusion of Delphi’s Proprietary Test, SET2,3™, into the Adaptive Randomization Process for the Ongoing I-SPY 2 TRIAL™

October 27, 2022 by Emily Granger

Houston, TX, October 27th, 2022 – Delphi Diagnostics, Inc and Quantum Leap Healthcare Collaborative™ (QLHC) announce the inclusion of Delphi’s SET2,3TM test for use in the I-SPY 2 TRIAL for patients with locally advanced breast cancer. The SET2,3TM test helps to determine which patients with HR+ tumors will benefit from endocrine therapy. Those patients whose […]

Filed Under: Uncategorized

Delphi DiagnosticsTM Inc. Announced the Issuance of a New U.S. Patent Covering the Sensitivity to Endocrine Therapy (SETER/PR) Test Through 2037

September 22, 2022 by Emily Granger

Patents recently issued in the US and allowed in Japan provide additional coverage for the company’s proprietary SETTM technologies for patients with HR+HER2- breast cancer and strengthens the company’s intellectual property portfolio. Houston, TX, September 22, 2022 – Delphi DiagnosticsTM Inc. today announced that the United States Patent and Trademark Office has issued US11,459,617 on […]

Filed Under: Uncategorized

SET2,3TM Results Can Determine Prognosis and Prediction of Benefit from Dose-Dense Chemotherapy in Estrogen Receptor-Positive (ER+) Breast Cancer Presented at ASCO 2022

June 13, 2022 by Emily Granger

For patients diagnosed with ER+ breast cancer and low endocrine sensitivity (a Low SET2,3 index), dose-dense chemotherapy was associated with superior disease-free survival (DFS) and overall survival (OS) outcomes when compared to non-dose-dense regimens. Houston, TX, June 13 2022 – Delphi Diagnostics Inc. announced today the inclusion of Delphi’s proprietary Sensitivity to Endocrine Therapy test, […]

Filed Under: Uncategorized

Footer

Join us on:

  • LinkedIn
  • Privacy Policy
  • Contact Us
  • News

Copyright © 2023 · Delphi Diagnostics, Inc.™ All rights reserved.